Pharma BD Deal Intelligence
A £9 billion all-stock deal that merged Glaxo and Wellcome into the world's largest drugmaker, adding Zovirax, Retrovir, and Imigran to a portfolio dangerously exposed to Zantac's looming patent cliff. The combination delivered scale and diversification, though integrating two distinct R&D cultures proved a slower grind than the headline size suggested.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Sir Richard Sykes stated we want to lead in this process not be carried along by it as Glaxo sought to address the looming expiry of its blockbuster Zantac…
The $14 billion cash and stock offer was 49% higher than closing price of Wellcome shares and seemed designed to discourage any competing bids according to…
The FTC reviewed the proposed merger of Glaxo plc and Wellcome plc, addressing competitive concerns in the market for anti-migraine and anti-emetic drugs.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Glaxo acquired Wellcome plc for approximately £9 billion (~$14.2B), creating Glaxo Wellcome plc, then the world's largest pharmaceutical company. The deal was driven by Glaxo's need to diversify beyond Zantac as its patent expiry loomed.
$4.0B Global Antiviral + Migraine Market (1995)
Herpes simplex is a lifelong infection (HSV-1 typically orolabial, HSV-2 typically genital) that cycles between latency and outbreaks of painful vesicular lesions; most carriers are asymptomatic or minimally symptomatic. Migraine is a chronic neurologic disorder affecting ~39M Americans, characterized by recurrent moderate-to-severe unilateral throbbing headache with nausea, photophobia, and phonophobia.
Herpes antivirals: Zovirax/generic acyclovir, Valtrex (valacyclovir, GSK) and Famvir (famciclovir, Novartis) are all nucleoside analog DNA polymerase inhibitors. Migraine: triptans (Imitrex/sumatriptan GSK; Maxalt/rizatriptan Merck; Relpax/eletriptan Pfizer; 5-HT1B/1D agonists) compete with newer CGRP antagonists Ubrelvy and Qulipta (AbbVie) and Nurtec ODT (Pfizer).
$3.0B Global HIV Antiretroviral Market (1995)
HIV/AIDS was the leading cause of death among Americans aged 25-44 in 1995, with mortality rates peaking at 16.2 per 100,000. Wellcome's Retrovir (AZT) was the first approved antiretroviral, and the combination therapy revolution (HAART) was just beginning to transform the epidemic.
HIV competitive landscape: GSK/ViiV leads with Triumeq and Dovato (dolutegravir integrase strand transfer inhibitor-based regimens) and long-acting Cabenuva (cabotegravir + rilpivirine). Gilead dominates with Biktarvy (bictegravir/FTC/TAF) and Descovy (FTC/TAF) for PrEP. Merck markets Isentress (raltegravir, INSTI) and Delstrigo (doravirine NNRTI-based).
Glaxo launches hostile bid for Wellcome Trust stake; largest UK corporate acquisition to date.
Glaxo acquires Wellcome for ~GBP9B ($14.2B), creating Glaxo Wellcome, then world largest pharma.
Glaxo Wellcome restructures R&D, cutting 10K jobs; closes Beckenham, opens Stevenage centre.
Glaxo Wellcome acquires Affymax (combinatorial chemistry leader) to bolster drug discovery.
By 1999, Glaxo Wellcome is world 3rd-largest pharma (~4% global share). HIV/asthma leader.
Merger delivered cost savings and scale but no sustained growth. Merged again with SmithKline Beecham in 2000.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Glaxo plc / Wellcome plc (this deal) | 1995 | $14.2B | 61 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| bioMerieux SA / BioFire Diagnostics Inc. | 2013 | $485M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 1995 deals · Infectious Disease deals